

DOCKET NO.: V0191.70030US00

IRW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Zavizion et al.  
Serial No.: 10/608,820  
Confirmation No.: 7999  
Filed: June 27, 2003  
For: METHODS TO SELECTIVELY INACTIVATE PARASITES IN  
BIOLOGICAL COMPOSITIONS  
Examiner: Tammy K. Field  
Art Unit: 1645

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 1<sup>st</sup> day of January, 2005.

  
Kristin J. Ketelhut

MAIL STOP AMENDMENT

Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- Information Disclosure Statement
- PTO Form 1449 with cited references
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check in the amount of \$180 is enclosed to cover the filing fee. If the fee is insufficient, the balance may be charged to Deposit Account 23/2825. A duplicate of this sheet is enclosed.


Respectfully submitted,  
*Zavizion et al., Applicant*

By:



Maria A. Trevisan, Reg. No.: 48,207  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2206  
Telephone: (617) 646-8000

Docket No.: V0191.70030US00  
Date: January 7, 2005  
x01/09/05x



DOCKET NO.: V0191.70030US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Zavizion et al.  
Serial No.: 10/608,820  
Confirmation No.: 7999  
Filed: June 27, 2003  
For: METHODS TO SELECTIVELY INACTIVATE  
PARASITES IN BIOLOGICAL COMPOSITIONS  
Examiner: Tammy K. Field  
Art Unit: 1645

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 7<sup>th</sup> day of January, 2005.

  
Kristin J. Ketelhut

---

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF  
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed more than three months after the filing date of this application and after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in this application.

The fee of \$180 as set forth in 37 C.F.R. §1.17(p) is enclosed.

847224.1

01/11/2005 EAREGAY1 00000029 10608820

01 FC:1806

180.00 OP

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

<u>Docket No.</u>	<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>
*V0191.70003US01	10/494,791	6 May 2004	Chapman et al.
*V0191.70028US01	10/513,743	5 November 2004	Plunkett et al.
*V0191.70031US00	10/679,932	6 October 2003	Purmal et al.

\*a copy of this reference is not provided as the Office hereby waives the requirement under 37 CFR 1.98(a)(2)(iii) for submitting a copy of each cited U.S. patent application filed after June 30, 2003 and for applications filed before June 30, 2003, or that entered the national stage before June 30, 2003, if they are scanned to Image File Wrapper system and are available on Private PAIR.

The Applicant would like to bring to the Examiner's attention the enclosed search report from a corresponding International or Foreign National Application.

<u>Docket No.</u>	<u>Serial No.</u>	<u>Mailing Date</u>	<u>Type of Communication(s)</u>
V0191.70008WO00	PCT/US96/14040	14 January 1997	International Search Report
V0191.70008WO00	PCT/US96/14040	9 December 1997	International Preliminary Examination Report
V0191.70010WO00	PCT/US98/09724	10 August 1998	International Search Report
V0191.70015WO00	PCT/US98/27814	11 May 1999	International Search Report
V0191.70030WO00	PCT/US2004/019986	9 November 2004	International Search Report
V0191.70030WO00	PCT/US2004/019986	9 November 2004	Written Opinion

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;

2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,  
*Zavizion et al., Applicant*

By:   
\_\_\_\_\_  
Maria A. Trevisan, Reg. No. 48,207  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2206  
Telephone: (617) 646-8000

Docket No.: V0191.70030US00  
Date: January 7, 2005  
x01/09/05x

FORM PTO-1449/A and B (Modified)

APPLICATION NO.: 10/608,820

ATTY. DOCKET NO.: V0191.70030US00

FILING DATE: June 27, 2003

CONFIRMATION NO.: 7999

APPLICANT: Zavizion et al.

GROUP ART UNIT: 1645

EXAMINER: Tammy K. Field

Sheet

of

7

## U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	*A1	3,487,157		Pierce et al.	12-30-1969
	*A2	3,492,289		Symm et al.	01-27-1970
	*A3	3,626,196		Arnaudin et al.	12-07-1971
	*A4	3,636,196		Bauer et al.	01-18-1972
	*A5	4,036,952		Bauer et al.	07-19-1977
	*A6	4,058,599		Bauer et al.	11-15-1977
	*A7	4,098,726		Wagner et al.	06-04-1978
	*A8	4,161,581		Wagner et al.	07-17-1979
	*A9	4,206,295		Wagner et al.	06-03-1980
	*A10	4,429,045		Bass et al.	01-31-1984
	*A11	4,482,342		Lueptow et al.	11-13-1984
	*A12	4,567,042		Acree et al.	01-28-1986
	*A13	4,585,735		Meryman et al.	04-29-1986
	*A14	4,668,214		Reeder	05-26-1987
	*A15	4,784,992		Reiner	11-15-1988
	*A16	4,841,023		Horowitz	06-20-1989
	*A17	5,000,951		Bass et al.	03-19-1991
	*A18	5,055,485		Gcacintov et al.	10-08-1991
	*A19	5,120,649		Horowitz et al.	06-09-1992
	*A20	5,229,012		Pall et al.	07-20-1993
	*A21	5,232,844		Horowitz et al.	08-03-1993
	*A22	5,250,303		Meryman et al.	10-05-1993
	*A23	5,298,016		Gordon	03-29-1994
	*A24	5,374,424		Kelsey et al.	12-20-1994
	*A25	5,418,130		Platz et al.	05-23-1995
	*A26	5,547,576		Onishi et al.	08-20-1996
	*A27	5,559,250		Cook et al.	09-24-1996
	*A28	5,601,972		Meryman	02-11-1997
	*A29	5,698,432		Oxford	12-16-1997
	*A30	5,691,132		Wollowitz et al.	11-25-1997
	*A31	5,808,011		Gawryl et al.	09-15-1998
	*A32	5,891,705		Budowsky et al.	04-06-1999
	*A33	6,004,741		Wollowitz et al.	12-21-1999
	*A34	6,004,742		Wollowitz et al.	12-21-1999
	*A35	6,017,691		Wollowitz et al.	01-25-2000
	*A36	6,093,564		Budowsky et al.	07-25-2000
	*A37	6,093,725		Cook et al.	07-25-2000
	*A38	6,114,108		Budowsky	09-05-2000
	*A39	6,136,586		Budowsky	10-24-2000

FORM PTO-1449/A and B (Modified)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/608,820		ATTY. DOCKET NO.: V0191.70030US00	
				FILING DATE: June 27, 2003		CONFIRMATION NO.: 7999	
				APPLICANT: Zavizion et al.			
				GROUP ART UNIT: 1645		EXAMINER: Tammy K. Field	
Sheet	2	of	7				

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	*A40	6,143,490		Cook et al.	11-07-2000
	*A41	6,171,777	B1	Cook et al.	01-09-2001
	*A42	6,177,441	B1	Cook et al.	01-23-2001
	*A43	6,194,139	B1	Wollowitz et al.	02-27-2001
	*A44	6,197,207	B1	Chapman et al.	03-06-2001
	*A45	6,218,100	B1	Wollowitz et al.	04-17-2001
	*A46	6,251,580	B1	Lin et al.	06-26-2001
	*A47	6,270,952	B1	Cook et al.	08-07-2001
	*A48	6,281,225	B1	Hearst et al.	08-28-2001
	*A49	6,352,695	B1	Budowsky et al.	03-05-2002
	*A50	6,369,048	B1	Budowsky et al.	04-09-2002
	*A51	6,410,219	B1	Cook et al.	06-25-2002
	*A52	6,420,570	B1	Wollowitz et al.	07-16-2002
	*A53	2001/0009756	A1	Hei et al.	07-26-2001
	*A54	2001/0018179	A1	Hei	08-30-2001
	*A55	2002/0042043	A1	Stassinopoulos	04-11-2002
	A56	2,553,696		Wilson et al.	05-22-1951
	A57	4,481,189		Prince	11-06-1984
	A58	4,540,573		Neurath et al.	09-10-1985
	A59	4,591,505		Prince	05-27-1986
	A60	4,613,501		Horowitz	09-23-1986
	A61	4,764,369		Neurath et al.	08-16-1988
	A62	4,820,805		Neurath et al.	04-11-1989
	A63	2003-0202986	A1	Budowsky et al.	10-30-2003
	A64	2004-0137419	A1	Pumal et al.	07-15-2004

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	*B1	EP	0 476 711	A2, A3	Nakai et al.	03-25-1992	
	*B2	EP	0 612 532	A2	Solvay Animal Health, Inc.	08-31-1994	
	*B3	JP	53-82735		Agency of Industrial Science and Technology	07-21-1978	
	*B4	JP	55-009056	A1	Shigematsu et al.	01-22-1980	Y- Abstract
	*B5	JP	6-805520		Ohwada et al.	03-22-1994	
	*B6	RO	101400			04-12-1992	Y- Abstract
	*B7	SU	594 771		Vsesoyuznyj Ni Yashchurnyj I [SU]	07-07-1993	

FORM PTO-1449/A and B (Modified)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/608,820		ATTY. DOCKET NO.: V0191.70030US00	
				FILING DATE: June 27, 2003		CONFIRMATION NO.: 7999	
				APPLICANT: Zavizion et al.			
				GROUP ART UNIT: 1645		EXAMINER: Tammy K. Field	
Sheet	3	of	7				

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	*B8	SU	1 768 636	A1	Poultry Veterinary Research Institute	08-16-1989	
	*B9	SU	1 809 836	A3	Vsesoyuznyj Ni Veterinarnyj I [SU]	04-15-1993	
	*B10	WO	91/04659	A1	American Red Cross	04-18-1991	
	*B11	WO	92/03157	A1	Solvay Animal Health, Inc.	03-05-1992	
	*B12	WO	92/04031	A1	Shanbrom	03-19-1992	
	*B13	WO	92/18161	A1	The Wellcome Foundation Limited	10-29-1992	
	*B14	WO	96/14737	A1	Steritech, Inc.	05-23-1996	
	*B15	WO	96/39818	A1	Cerus Corporation	12-19-1996	
	*B16	WO	96/39820	A1	Cerus Corporation	12-19-1996	
	*B17	WO	97/07674	A1	Pentose Pharmaceuticals, Inc.	03-06-1997	
	*B18	WO	97/15685	A1	Winnacker	05-01-1997	
	*B19	WO	97/21346	A1	Cerus Corporation	06-19-1997	
	*B20	WO	98/30327	A1	Cerus Corporation	07-16-1998	
	*B21	WO	98/30545	A1	Cerus Corporation	07-16-1998	
	*B22	WO	98/45415	A1	Pentose Pharmaceuticals, Inc.	10-15-1998	
	*B23	WO	99/03976	A2	Cerus Corporation	01-28-1999	
	*B24	WO	99/17802	A1	Pentose Pharmaceuticals, Inc.	04-15-1999	
	*B25	WO	99/26476	A1	Cerus Corporation	06-03-1999	
	*B26	WO	99/34791	A1	Pentose Pharmaceuticals, Inc.	07-15-1999	
	*B27	WO	99/34914	A1	Cerus Corporation	07-15-1999	
	*B28	WO	99/34915	A1	Cerus Corporation	07-15-1999	
	*B29	WO	99/63981		Cerus Corporation	12-19-1999	
	*B30	WO	00/74731	A1	Baxter International Inc.	12-14-2000	
	*B31	WO	00/74806	A1	Baxter International Inc.	12-14-2000	
	*B32		009655595			10-15-1992	Abstract
	*B33		010096757			07-07-1993	Abstract
	B34	SU	1 177 297		Inst Chimii Bashkirskogo [SU]	09-07-1985	Abstract
	B35	SU	1 266 847		Borisenko et al. [SU]	10-30-1986	Abstract
	B36	SU	1 300 021		Komarov et al. [SU]	03-30-1987	Abstract
	B37	SU	1 364 620		Inst Khim Fiz An SSSR [SU]	01-07-1988	Abstract
	B38	SU	1 696 505		Inst Khim Fiz Im N N Semenova [SU]	12-07-1991	Abstract
	B39	WO	00/43549	A1	V.I. Technologies, Inc.	07-27-2000	
	B40	WO	03/066806	A2	V.I. Technologies, Inc.	08-14-2003	
	B41	WO	03/093512	A1	V.I. Technologies, Inc.	11-13-2003	

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	*C1	AMOR et al., Use of N-acetyleneimine [AEI] for the inactivation of Semliki Forest virus in vitro. J Med Virol. 1986 Aug;19(4):367-76.		
	*C2	ATWELL et al., Synthesis, DNA interactions and biological activity of DNA minor groove targeted polybenzamide-linked nitrogen mustards. Bioorg Med Chem. 1995 Jun;3(6):679-91.		

<b>FORM PTO-1449/A and B (Modified)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/608,820		ATTY. DOCKET NO.: V0191.70030US00	
				FILING DATE: June 27, 2003		CONFIRMATION NO.: 7999	
				APPLICANT: Zavizion et al.			
				GROUP ART UNIT: 1645		EXAMINER: Tammy K. Field	
Sheet	4	of	7				

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	*C3	BAHNEMANN et al., Inactivation of viruses in serum with binary ethyleneimine. J Clin Microbiol. 1976 Feb;3(2):209-10.		
	*C4	BAHNEMANN et al., Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethyleneimine. Vaccine. 1990 Aug;8(4):299-303.		
	*C5	BIENIARZ et al., A facile, high-yielding method for the conversion of halides to mercaptans. Tetrahedron Lett. 1993;34:939-42.		
	*C6	BRIEL et al., Identification of New Aqueous Chemical Degradation Products of Isophosphoramidate Mustard. J Pharm Biomed Anal. 2001 Jun;25 (3-4): 669-78.	Y - Abstract	
	*C7	BUDOVSKY et al., [Inactivations of the phage MS2 infectivity by the action of ethyleneimines] Bioorg Khim. 1985;11(7):989-91. Russian. Abstract.		
	*C8	BUDOWSKY et al., Problems and prospects for preparation of killed antiviral vaccines. Adv Virus Res. 1991;39:255-90.		
	*C9	BUDOWSKY et al., Principles of selective inactivation of the viral genome: Dependence of the rate of viral RNA modification on the number of protonizable groups in ethyleneimine oligomers. Vaccine Res. 1996;5(1):29-39.		
	*C10	BUDOWSKY et al., Principles of selective inactivation of viral genome. V. Rational selection of conditions for inactivation of the viral suspension infectivity to a given extent by the action of beta-propiolactone. Vaccine. 1991 May;9(5):319-25.		
	*C11	BURRAGE et al., Inactivation of viruses by aziridines. Dev Biol. 1999;102:131-9.		
	*C12	CHARACHE et al., Evaluation of extracorporeal alkylation of red cells as a potential treatment for sickle cell anemia. Blood. 1976 Mar;47(3):481-8.		
	*C13	CREECH et al., Antitumor and mutagenic properties of a variety of heterocyclic nitrogen and sulfur mustards. J Med Chem. 1972 Jul;15(7):739-46.		
	*C14	DANAO et al., Nitrogen mustard as induction therapy for rheumatoid arthritis: clinical and immunologic effects. J Rheumatol. 1992 Nov;19(11):1683-6.		
	*C15	DERMER et al., editors. Ring-destroying reactions of aziridines. in Chapter 3: Reactions of aziridines. in Ethyleneimine and other aziridines: Chemistry and applications. Academic Press: New York and London, 1969. p. 249-285.		
	*C16	DRAKE et al., Effect of nitrogen mustard on virus of serum hepatitis in whole blood. Proc Soc Exp Biol Med. 1952 Jun;80(2):310-13.		
	*C17	EARLEY et al., Reactions of ethyleneimines. IX. The mechanisms of ring openings of ethyleneimines in acidic aqueous solutions. J Am Chem Soc. 1958 Jul 5;80: 3458-62.		
	*C18	FERGUSON et al., Bacterial mutagenicity studies of DNA-intercalating aniline mustards: an insight into the mode of action of a novel class of anti-tumour drugs. Anticancer Drug Des. 1989 Oct;4(3):209-19.		
	*C19	FERGUSON et al., DNA-directed aniline mustards with high selectivity for adenine or guanine bases: mutagenesis in a variety of Salmonella typhimurium strains differing in DNA-repair capability. Mutat Res. 1994 Apr;321(1-2):27-34.		
	*C20	FRIES et al., <sup>31</sup> P NMR and Chloride Ion Kinetics of Alkylating Monoester Phosphoramidates. J Med Chem. 1991 Feb;34(2): 565-9.		
	*C21	GABLER et al., Developments in Industrial Microbiology. 1984;25:381-97.		
	*C22	GAO et al., Minor groove binding of SN6999 to an alkylated DNA: molecular structure of d(CGC[e6G]AATTCGCG)-SN6999 complex. Biochemistry. 1993 Sep 21;32(37):9639-48.		
	*C23	GOURDIE et al., DNA-directed alkylating agents. 1. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the reactivity of the mustard. J Med Chem. 1990 Apr;33(4):1177-86.		



FORM PTO-1449/A and B (Modified)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/608,820		ATTY. DOCKET NO.: V0191.70030US00	
				FILING DATE: June 27, 2003		CONFIRMATION NO.: 7999	
				APPLICANT: Zavizion et al.			
				GROUP ART UNIT: 1645		EXAMINER: Tammy K. Field	
Sheet	5	of	7				

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	*C24	GOURDIE et al., Synthesis and evaluation of DNA-targeted spatially separated bis(aniline mustards) as potential alkylating agents with enhanced DNA cross-linking capability. J Med Chem. 1991 Jan;34(1):240-8.		
	*C25	GRAVATT et al., DNA-directed alkylating agents. 6. Synthesis and antitumor activity of DNA minor groove-targeted aniline mustard analogues of pibenzimol (Hoechst 33258). J Med Chem. 1994 Dec 9;37(25):4338-45.		
	*C26	GRAVATT et al., DNA-directed alkylating agents. 4. 4-anilinoquinoline-based minor groove directed aniline mustards. J Med Chem. 1991 May;34(5):1552-60.		
	*C27	GRIFFIN et al., Kinetics of Activation and in Vivo Muscarinic Receptor Binding of N-(2-bromoethyl)-4-PiperidinyI Diphenylacetate: an Analog of 4-DAMP Mustard J. Pharmacol Exp Ther 1993 Jul; 266(1) 301-5.		
	*C28	HAMZA, Quantum Molecular Modeling of the Interaction Between Guanine and Alkylating Agents 2 Nitrogen Mustard. J Biomol Struct Dyn. 1996 Jun; 13(6):915-24.		
	*C29	HARTMAN et al., Preparation and sterilization of blood plasma. Am J Clin Pathol. 1954 Mar;24(3):339-48.		
	*C30	HARTMAN et al., On the chemical sterilization of blood and blood plasma. Proc Soc Exp Biol Med. 1949;70:248-54.		
	*C31	HARTMAN et al., Four-year study concerning the inactivation of viruses in blood and plasma. presented at the 55 <sup>th</sup> Annual Meeting of the American Gastroenterological Association, San Fransisco, CA. 1954.		
	*C32	HASSANAIN et al., Preliminary findings for an inactivated African horsesickness vaccine using binary ethyleneimine. Rev Elev Med Vet Pays Trop. 1992;45(3-4):231-4.		
	*C33	HEMMINKI, Reactions of Nitrogen Mustards with DNA IARC Sci Publ. 1986; (78):55-70		
	*C34	HEMMINKI et al., DNA adducts of nitrogen mustards nad ethyleneimines. in DNA Adducts: Identification and Biological Significance, IARC Sci Publ. 1994;313-21.		
	*C35	KING, Evaluation of different methods of inactivation of Newcastle disease virus and avian influenza virus in egg fluids and serum. Avian Dis. 1991 Jul-Sep;35(3):505-14.		
	*C36	KNORRE et al., [Reactive oligonucleotide derivatives as potential antiviral preparations] Vopr Virusol. 1985 Sep-Oct;30(5):524-9. Review. Russian. Previously presented as Problems of Virology.		
	*C37	KOCHETOV et al., editors. Sequence of nucleotides in the polynucleotide chain. in Chapter 1: Structure of nucleic acids. in Organic Chemistry of Nucleic Acids. Plenum Press: London and New York, 1971. p. 48-55.		
	*C38	KOHN et al., Mechanisms of DNA Sequence Selective Alkylation of Guanine-N7 Positions by Nitrogen Mustards. Biochem Pharmacol. 1988 May 1; 37(9): 1799-800.		
	*C39	KOSTYANOVSKII et al., Oligomers of aziridines and N-β-aziridinoethylamides. Bull Acad Sci USSR. 1989;37:2315- 23.		
	*C40	LEE et al., In vitro cytotoxicity of GC sequence directed alkylating agents related to distamycin. J Med Chem. 1993 Apr 2;36(7):863-70.		
	*C41	LOBOSTOV et al., Probl Virusol Mol Biol Gistol S-kh Zhivotn. 198; 4-6.		
	*C42	LOGRIPPO et al., Chemical and combined methods for plasma sterilization. Bibl Haematol. 1958;14(7):225-30.		
	*C43	MATTES et al., GC-rich regions in genomes as targets for DNA alkylation. Carcinogenesis. 1988 Nov;9(11):2065-72.		
	*C44	MOLLISON et al., Blood Transfusion in Clinical Medicine, Tenth Ed. Blackwell Science, 1997. p4.		
	*C45	MOORE et al., In vivo viability studies of two additive solutions in the postthaw preservation of red cells held for 3 weeks at 4 degrees C. Transfusion. 1993 Sep;33(9):709-12.		

FORM PTO-1449/A and B (Modified)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/608,820		ATTY. DOCKET NO.: V0191.70030US00	
				FILING DATE: June 27, 2003		CONFIRMATION NO.: 7999	
				APPLICANT: Zavizion et al.			
				GROUP ART UNIT: 1645		EXAMINER: Tammy K. Field	
Sheet	6	of	7				

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	*C46	MURPHY et al., Chapter 2: Virus Taxonomy. <i>in</i> Virology, Third Edition. Fields et al., editors. Lippincott-Raven Publishers: Philadelphia and New York, 1996. ISBN 0-7817-0253-4.		
	*C47	PRAKASH et al., Differences in sequence selectivity of DNA alkylation by isomeric intercalating aniline mustards. <i>Chem Biol Interact.</i> 1990;76(2):241-8.		
	*C48	PRICE et al., Relative Reactivities for Monofunctional Nitrogen Mustard Alkylation of Nucleic Acid Components. <i>Biochim Biophys Acta.</i> 1968 Sep 24; 166(2):327-59		
	*C49	PRODOUZ et al., Inhibition by albumin of merocyanine 540-mediated photosensitization of platelets and viruses. <i>Transfusion.</i> 1991 Jun;31(5):415-22.		
	*C50	RACE et al., An experimental chemically inactivated HIV-1 vaccine induces antibodies that neutralize homologous and heterologous viruses. <i>Vaccine.</i> 1995 Jan;13(1):54-60.		
	*C51	ROTH et al., Metabolic effects of antiscikling amounts of nitrogen and nor-nitrogen mustard on rabbit and human erythrocytes. <i>Blood.</i> 1975 Jun;45(6):779-88.		
	*C52	SPRINGER et al., Isophosphoramidate Mustard and Its Mechanism of Bisalkylation. <i>J Org Chem.</i> 1998 Oct. 16; 63(21):7218-7222.		
	*C53	TANIRBERGENOV et al., [Characteristics of the mutagenic and toxic effects of ethylene imine and its oligomers. Comparative study in the automated SOS-chromotest system and in standard bacterial test systems] <i>Genetika.</i> 1988 Apr;24(4):763-5. Russian.	Yes	
	*C54	THANEI-WYSS et al., Interaction of quaternary ammonium compounds with acetylcholinesterase: characterization of the active site. <i>Eur J Pharmacol.</i> 1989 May 11;172(2):165-73.		
	*C55	TWOMEY et al., Structure and immunogenicity of experimental foot-and-mouth disease and poliomyelitis vaccines. <i>Vaccine.</i> 1995 Nov;13(16):1603-10.		
	*C56	VALU et al., DNA-directed alkylating agents. 3. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the length of the linker chain. <i>J Med Chem.</i> 1990 Nov;33(11):3014-9.		
	*C57	VANETTEN et al., Effects of hydrogen-bond formation by phenols on the conformational equilibrium of <i>trans</i> -1,2-Dimethyl-3-isopropylaziridine. <i>J Org Chem.</i> 1968 Oct; 33(10):3904-7.		
	*C58	VERSCHAEVE et al., Mutagenicity of ethyleneimine. <i>Mutat Res.</i> 1990 Jan;238(1):39-55.		
	*C59	VLASOV et al., The feasibility of blocking influenza infections by means of alkylating derivatives of oligonucleotides. <i>Mol Gen Microbiol Virol.</i> 1984.		
	*C60	WAGNER et al., Approaches to the reduction of viral infectivity in cellular blood components and single donor plasma. <i>Transfus Med Rev.</i> 1991 Jan;5(1):18-32.		
	*C61	WARRINGTON et al., Derivatives of aziridine as inactivants for foot-and-mouth disease virus vaccines. <i>Am J Vet Res.</i> 1973 Aug;34(8):1087-91.		
	*C62	WICKHAM et al., DNA-binding properties and antitumour activity of monofunctional alkylating groups attached to the DNA-intercalating chromophore phenanthridine: n-bromoalkylphenanthridinium bromides. <i>Biochim Biophys Acta.</i> 1991 Apr 9;1073(3):528-37.		
	*C63	WILKE et al., Parenteral nitrogen mustard for inflammatory arthritis. <i>Cleve Clin J Med.</i> 1990 Oct;57(7):643-6.		
	*C64	YAMAMOTO et al., Mechanism of inactivation of DNA and RNA bacteriophages by alkylating agents in vitro. <i>Cancer Res.</i> 1966 Nov;26(11):2301-6.		
	*C65	YANG, C. et al The Preparation of an Inactivated Antigen for Bluetongue Serology Zentralbl Veterinarmed [B] 1984 May; 31(4); 290-6.		
	*C66	ZALESSKAYA et al., Inactivation of viral genome by beta-propiolactone and ethylenimines using the bacteriophage MS-2 as an example. Dissertation presented 1988 in Moscow (M., 1988), degree conferred on May 4, 1989 (IH&05.04.89), catalogued in the Russian State Library (formerly the Lenin State Library).		
	*C67	[No Author Listed] Quick Reference: Requirements for Vaccines and Diagnostic Biologicals. aleffgroup.com, pages 1-3.		

<b>FORM PTO-1449/A and B (Modified)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/608,820		ATTY. DOCKET NO.: V0191.70030US00	
				FILING DATE: June 27, 2003		CONFIRMATION NO.: 7999	
				APPLICANT: Zavizion et al.			
				GROUP ART UNIT: 1645		EXAMINER: Tammy K. Field	
Sheet	7	of	7				

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	C68	ABE et al., Analysis of viral DNA, protein and envelope damage after methylene blue, phthalocyanine derivative or merocyanine 540 photosensitization. Photochem Photobiol. 1995 Apr;61(4):402-9.		
	C69	AUBUCHON et al., Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a Phase I clinical study. Transfusion. 2002 Feb;42(2):146-52.		
	C70	JEONG et al., Thermal decomposition and desorption of diethylamido of tetrakis (diethylamido) zirconium (TDEAZr) on Si(100). Surf Rev Lett. 2003;10(1):121-5. Abstract.		
	C71	LAZO et al., Broad-spectrum virus reduction in red cell concentrates using INACTINE PEN110 chemistry. Vox Sang. 2002 Nov;83(4):313-23.		
	C72	MUSSER et al., Alkylation of DNA with aziridine produced during the hydrolysis of N,N',N"-triethylenethiophosphoramidate. Chem Res Toxicol. 1992 Jan-Feb;5(1):95-9.		
	C73	TUBARO et al., [The use of cytostatic drugs in fields other than antineoplastic therapy] Boll Chim Farm. 1967 Nov;106(11):715-9. Italian.	No	
	C74	VALERI et al., A comparison of methods of determining the 100 percent survival of preserved red cells. Transfusion. 1984 Mar-Apr;24(2):105-8. Abstract.		
	C75	ZAVIZION et al., The INACTINETM PEN110 chemistry eradicates the parasites that cause Chagas' disease, malaria, and babesiosis. Vox Sang. 2002 Aug;83(2):118-9.		
	C76	[No Author Listed] Henry et al., editors. Clinical Diagnosis and Management by Laboratory Methods, 18 <sup>th</sup> Edition. W.B. Saunders Company: Philadelphia, 1991. p7, 932.		
	C77	[No Author Listed] Toronto Research Chemicals, Inc. Product Results. <a href="http://www.trc-canada.com/product.lasso?product=A174000">http://www.trc-canada.com/product.lasso?product=A174000</a> . N-Acetyleneimine. Printed 7/23/22003.		

EXAMINER:	DATE CONSIDERED:
-----------	------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/877,838 filed June 8, 2001, Serial No. 09/161,030 filed September 25, 1998, Serial No. 08/855,378 filed May 13, 1997, Serial No. 09/877,838 filed July 5, 2000, Serial No. 09/609,687 filed July 5, 2000, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. § 120, and the copy was provided in the earlier application.]